Navigation Links
WuXi PharmaTech Announces Second Quarter 2011 Results
Date:8/10/2011

increase in non-GAAP operating expenses driven by the hiring of new senior staff and sales and marketing personnel, RMB appreciation, and building of our biology research capabilities.Second-quarter 2011 non-GAAP net income grew 10.4% year over year to $22.0 million due to the 10.8% increase in non-GAAP operating income and higher interest income from short-term investments.

Diluted non-GAAP earnings per ADS grew 9.3% year over year to 29 cents, mainly due to the 10.4% increase in non-GAAP net income, offset by slightly higher share count due to the exercise of stock options.

2011 Financial GuidanceThe company announces the following update of its full-year 2011 financial guidance:

  • Total net revenues of $400-407 million, which represents 20-22% growth
  • Growth in net revenues of China-based Laboratory Services of 14-15%
  • Growth in net revenues of U.S.-based Laboratory Services of 5-7%
  • Growth in net revenues of Manufacturing Services of 80-90%
  • Decrease in gross margin of about 1 percentage point
  • GAAP operating margin of about 21% and non-GAAP operating margin of about 24%
  • Capital expenditures of about $60 million
  • GAAP effective tax rate of about 18%

  • The Company provides the following guidance for third-quarter 2011 performance:

  • Total net revenues of $100-103 million, or 19-23% year-over-year growth
  • Laboratory Services revenues of $82-84 million, Manufacturing Services net revenues of $18-19 million
  • GAAP and non-GAAP operating margins of about 21% and 24%, respectively

  • WUXI PHARMATECH (CAYMAN) INC.UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands of U.S. dollars, except ordinary share, ADS and par value data)June 30, 2011December 31, 2010Assets: 

     

     

     Current assets:

     

     

     

     Cash
    '/>"/>

    SOURCE WuXi PharmaTech (Cayman) Inc
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
    2. WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release
    3. WuXi PharmaTech Announces First-Quarter 2011 Results
    4. WuXi PharmaTech Files 2010 Annual Report on Form 20-F
    5. WuXi PharmaTech Schedules First-Quarter 2011 Earnings Release
    6. Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility
    7. WuXi PharmaTech Schedules Fourth-Quarter 2010 Earnings Release
    8. WuXi PharmaTech Provides Update of 2010 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
    9. WuXi PharmaTech Presents 2010 Life Science and Chemistry Awards
    10. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting
    11. WuXi PharmaTech Announces Third-Quarter 2010 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
    (Date:10/30/2014)... -- , La fórmula de leche ... tolerancia a la proteína de leche de vaca  ... leche de la vaca (APLV) es la principal alergia alimentaria ... APLV se trataba eliminando las proteínas lácteas de ... posible adquirir tolerancia oral en un número significativo ...
    (Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
    Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
    ... 28, 2011 Nile Therapeutics, Inc. (Nasdaq: ... novel therapeutics for heart failure patients, today announced plans ... ) on the clinical development of Nile,s proprietary natriuretic ... disease applications. "We are very pleased to ...
    ... Feb. 28, 2011 PAREXEL International Corporation (Nasdaq: ... presenting at the Raymond James Investors Conference in Orlando, FL. ... be making a presentation on PAREXEL at 2:50 p.m.  ET ... of this presentation will be available through the "Investors" ...
    Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3PAREXEL International to Present at Raymond James Investors Conference 2
    (Date:10/28/2014)... that aims to make personalized medicine a reality for ... across British Columbia. , The "Genomics for Precision Drug ... of its kind in North America. The project is ... (BCPhA), with the research component led by a team ... Sciences (UBC). It will position the pharmacist as the ...
    (Date:10/27/2014)... price tag for informal caregiving of elderly people by ... $522 billion a year, according to a new RAND ... care at minimum wage would cost $221 billion, while ... $642 billion annually. , The study, published online ... estimates about the value of informal caregiving by making ...
    (Date:10/27/2014)... different role than previously thought in the opening and ... out of our cells, researchers at Johns Hopkins report. ... right concentrations of sodium and calcium ions in cells ... processes. The new study reveals that a form of ... channels wide. The finding is likely to bring new ...
    (Date:10/27/2014)... The 2014 Sharp­Brains Vir­tual ... world’s top sci­en­tists and inno­va­tors work­ing on ... via neuroscience-based inno­va­tion. , Indi­vid­u­als and insti­tu­tions ... bil­lion in 2014 in web-based, mobile and ... func­tion. Growth is poised to con­tinue, fueled ...
    (Date:10/27/2014)... Agency (EMA), an EU agency, has gathered information on ... European ADR database, EudraVigilance. Both authorities and pharmaceutical companies ... the database, which provides new knowledge about unknown and ... drug reaction reports on asthma medications approved for – ... (2007 to 2011). In the light of the total ...
    Breaking Medicine News(10 mins):Health News:Genomics helps pharmacists target the right drugs for the right patient 2Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 2Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 3Health News:200 Experts to Discuss and Shape the Future of Brain Health, Gathered Around a Virtual Table 4Health News:Adverse drug reactions in children following use of asthma medications 2
    ... a pregnancy take a general multivitamin supplement in the ... them and their baby, however a recent survey suggests ... in unborn babies but many women do not consider ... based on a recent survey. The survey conducted by ...
    ... has donated $50,000 to Gilda's Club Worldwide, //an organization that ... in a statement: "When children have cancer, or when their ... places they can turn to for support." , ,"Gilda's ... helping children in need, and so I am very happy ...
    ... People suffering from Alzheimer’s disease can have loss of ... to test their visual clarity., ,Alzheimer’s disease affects ... symptoms of the disease are decreasing memory, ability to ... Alzheimer’s disease are often disoriented too much to be ...
    ... may lack a gene called estrogen receptor beta and not ... research funded by National Institute of Environmental Health Sciences reported ... role in moving the egg outside the ovary to be ... is found otherwise throughout in the female reproductive tissues, women ...
    ... people were infected with HIV by 2004.// This puts the prevalence ... South Africa 's total population is 46.9 million. , ... far higher than the estimate of 4.5 million given by the ... ,The health department said that between 6.29 million ...
    ... microRNAs may be responsible for birth defects, cancer and ... Institute have used genetically modified mice to see how ... animals. When the mice were grown without the microRNA ... limbs., ,MicroRNA (miRNA) are small RNA molecules that ...
    Cached Medicine News:Health News:Britney Spears Donates $50 000 To Support Cancer Patients 2Health News:Britney Spears Donates $50 000 To Support Cancer Patients 3Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 2Health News:Over Six Million HIV Infected People In South Africa- Finds A Survey 3
    Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
    Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
    1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish....
    Solid lower plate with outside width 28 mm. Open upper plate. Serrated handle with locking thumb screw and polished finish. Right....
    Medicine Products: